On Monday, Pliant Therapeutics Inc. PLRX announced that it would discontinue the BEACON-IPF Phase 2b trial, which evaluated bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).The move follows a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB) and a secondary review and recommendation by an outside expert panel.While an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuati ...